Merck & Co. Inc. is making the prudent choice in opting not to pursue regulatory approval for the CETP inhibitor anacetrapib, avoiding what could have been a tricky review with only the possible reward being entry into the commercial quagmire of the cholesterol market that has hindered uptake of the PCSK9 inhibitor class.
Merck Calls It Quits On Anacetrapib
Despite success in REVEAL outcomes trial, Merck will not submit the for the cholesteryl ester transfer protein (CETP) inhibitor for regulatory approval.
